Although several genes or genetic loci that are either responsible for or confer susceptibility to familial hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM) have been identified, genetic defects that underlie nonfamilial HCM or DCM remain to be characterized. An allelic association study for the angiotensin converting enzyme (ACE) and angiotensinogen genes has now been performed with 71 patients with nonfamilial HCM, 88 patients with nonfamilial DCM, and 122 healthy control subjects in the Japanese population. The distribution of ACE genotypes for an insertion/deletion (I/D) polymorphism in intron 16 did not differ significantly among control subjects and patients with HCM or DCM. Similarly, the distributions of angiotensinogen genotypes for methionine-235-threonine (M235T) and threonine-174-methionine (T174M) polymorphisms did not differ significantly among the three groups. H ypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy with predominant involvement of the interventricular septum in the absence of hypertension, valvular heart disease, or other apparent causes of hypertrophy.
H ypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy with predominant involvement of the interventricular septum in the absence of hypertension, valvular heart disease, or other apparent causes of hypertrophy. 1, 2 The main cardiac pathological caracteristics include myocyte hypertrophy, which is also associated with other cardiac diseases, as well as myocyte and myofibrillar disarray, which is the hallmark of HCM. 1, 2 Familial HCM, which is inherited as an autosomal dominant disease, 1,2 can be caused by point mutations in the ␤-cardiac myosin heavy chain, [1] [2] [3] [4] ␣-tropomyosin, and cardiac troponin T genes. 1, 2, 5 Although about one-half of the HCM cases are nonfamilial, 1 causative gene defects have not been identified for nonfamilial HCM.
Dilated cardiomyopathy (DCM), characterized by ventricular dilatation and impaired systolic contraction, is manifested clinically by pump failure or sudden death. 1 Complications of DCM, such as heart failure and refractory ventricular arrhythmia, are often lethal unless treated by cardiac transplantation. Genetic loci responsible for familial DCM have been mapped to chromosomes 1p1-1q1 6 , 1q32 7 , and 3p22-p25. 8 In addition, the defect in dystrophin gene 9, 10 and multiple deletions of mitochondrial DNA 11 appear to contribute to the susceptibility to DCM in some families. Although 80% of DCM cases are not inherited, 12 the genetic defects that underlie nonfamilial DCM have not been identified. The identification of genes responsible for nonfamilial HCM and DCM is complicated by the fact that the phenotype expression of both diseases may be influenced by additional modifying genes that affect cardiovascular function.
The renin-angiotensin system contributes to the pathophysiology of various cardiovascular diseases and may play an autocrine or paracrine role in cardiac remodeling and fibrosis. 13, 14 Angiotensin converting enzyme (ACE), an important regulator of the reninangiotensin system, catalyzes the production of angiotensin II and the degradation of bradykinin. Various experimental and clinical studies have implicated ACE and these two peptides in the development of cardiac hypertrophy 13, 15, 16 and atherosclerosis. 13, 17 Cloning of the ACE gene revealed a 287 base pair (bp) insertion/deletion (I/D) polymorphism in intron 16, 18 -20 and this polymorphism was shown to be correlated with the concentration and activity of ACE in plasma. 21, 22 Marian et al 23 showed that the DD genotype of ACE is present in excess in patients with HCM, especially in HCM families with a pronounced history of sudden cardiac death, as compared with unaffected relatives. Lechin et al 24 showed that the ACE gene modifies the phenotypic expression of hypertrophy in individuals with HCM, whereas Yoneda et al 25 also detected an association of the D allele with sporadic HCM. However, the role of ACE genotype in the genesis and progression of nonfamilial HCM is not clear.
Raynolds et al 26 showed that the DD genotype of ACE is a risk factor for the development of end-stage heart failure caused by ischemic or idiopathic DCM. However, Montgomery et al 27 and Sanderson et al 28 failed to detect an association between ACE genotype and idiopathic DCM in white and Chinese populations, respectively. Thus, the role of ACE genotype in the pathogenesis of idiopathic nonfamilial DCM remains controversial. Angiotensinogen is synthesized primarily by the liver and released into the circulation, where it is cleaved by renin to generate angiotensin I. The latter is subsequently converted to angiotensin II by ACE. Linkage analysis has detected an association between the angiotensinogen gene, located at chromosome 1q4, and essential hypertension: Two exon-2 variants, one with threonine instead of methionine at position 235 (M235T) and one with methionine rather than threonine at position 174 (T174M), are significantly related to high blood pressure. 29 However, the role of these angiotensinogen gene polymorphisms in nonfamilial HCM and DCM has not been determined.
We have now investigated the association of polymorphisms of the ACE and angiotensinogen genes, alone and in combination, with nonfamilial HCM and DCM. We also analyzed the relationship between ACE and angiotensinogen genotypes and echocardiographic parameters as indicators of the severity or progression of disease.
METHODS

Study Population
The study population consisted of 281 unrelated Japanese subjects (71 patients with HCM, 88 patients with DCM, and 122 healthy individuals) who had visited 14 participating hospitals (see Appendix) between July 1994 and June 1995 either for a medical checkup or because they were experiencing various symptoms. The diagnosis of HCM or DCM was based on patient history, physical examination, electrocardiogram, chest x-ray, echocardiography, left ventriculography, and coronary angiography. All patients were free of hypertension, ischemic heart disease, valvular heart disease, congenital malformations of the heart or vessels, and intrinsic pulmonary, renal, or metabolic diseases. Endomyocardial biopsies were also obtained to confirm the diagnosis. Healthy individuals were selected as a normal control group. They had visited the hospitals or clinics for an annual medical checkup and did not exhibit any serious disorders. Informed consent was obtained from all subjects.
The age of the control subjects and patients with HCM or DCM was 60.2 Ϯ 11.0, 59.1 Ϯ 10.3, and 59.0 Ϯ 13.0 years (means Ϯ SD), respectively. The body mass index of control subjects and patients with HCM or DCM was 22.6 Ϯ 3.3, 23.9 Ϯ 3.4, and 22.4 Ϯ 4.4 kg/m 2 (means Ϯ SD), respectively. Neither characteristic differed significantly among the three groups.
Isolation of Genomic DNA Venous blood (7 mL) was collected into tubes containing EDTA (disodium salt; final concentration, 50 mmol/L), peripheral blood leukocytes were isolated, and genomic DNA was ex-tracted from these cells with a DNA extraction kit (Biologica, Nagoya, Japan).
Genotyping of ACE Gene Polymorphism
The ACE gene I/D polymorphism was detected by polymerase chain reaction (PCR) analysis. The respective fragments from intron 16 were amplified as previously described, 20 with minor modifications. Sense and antisense primers were 5Ј-CTGGAGACCACTCCCATC-CTTTCT-3Ј and 5Ј-GATGTGGCCATCACATTCGT-CAGAT-3Ј, respectively. Reactions were performed in a total volume of 50 L containing 1 g of genomic DNA, 40 pmol of each primer, 0.2 mmol/L of each deoxynucleoside triphosphate, 1.25 U of Taq DNA polymerase (Takara, Otsu, Japan), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , and 10 mmol/L Tris-HCl (pH 8.3). The thermocycling procedure was performed with a Gene Amp PCR System 9600-R (Perkin-Elmer, Norwalk, CT) and consisted of initial denaturation at 94°C for 4 min; 30 cycles of denaturation at 94°C for 1 min, annealing at 58°C for 1 min, and extension at 72°C for 2 min, followed by a final extension at 74°C for 7 min. The PCR products were analyzed by 2% agarose gel electrophoresis and visualized by ethidium bromide staining. PCR amplification generated 490-or 190-bp fragments (or both, in the case of heterozygotes), corresponding to the I and D alleles, respectively.
Genotyping of Angiotensinogen Gene Polymorphisms Genotype for the M235T polymorphism was determined by PCR and restriction fragment length polymorphism (RFLP) analysis as described by Russ et al, 30 with minor modifications. The sense and antisense primers were 5Ј-CCGTTTGTGCAGGGCCTG-GCTCTCT-3Ј and 5Ј-CAGGGTGCTGTCCACACTG-GACCCC-3Ј, respectively. PCR was performed with a reaction mixture identical (with the exception of the primers) to that used for ACE genotyping. The thermocycling procedure consisted of initial denaturation at 90°C for 3 min; 10 cycles of denaturation at 94°C for 1 min, annealing at 68°C for 1 min, and extension at 72°C for 1 min; 30 cycles of denaturation at 94°C for 30 sec, annealing at 68°C for 30 sec, and extension at 72°C for 30 sec; and a final extension at 72°C for 10 min. A portion (2 L) of the unpurified PCR products was then diluted to 10 L in restriction enzyme buffer and incubated with 12 U of Tth111-I (Takara) at 65°C for Ն2 h. In the absence of the M235T variant (AA genotype), the 164-bp amplification product remained intact. The PCR product of M235T homozygotes (aa genotype) was cleaved by Tth111-I to yield a 140-bp fragment. Both 164-and 140-bp fragments were apparent for heterozygotes (Aa genotype).
Genotype for the T174M variant was also determined by PCR-RFLP analysis. 31 The sense and antisense primers were 5Ј-TACAGGCAATCCTGGGTGT-TCCTTG-3Ј and 5Ј-AGCAGAGAGGTTTGCCTTAC-CTTG-3Ј, respectively. PCR amplification was performed as described for ACE genotyping. A 2-L portion of nonpurified PCR products was diluted to 10 L in the restriction enzyme buffer and incubated with 5 U of Nco I (Takara) at 37°C for Ն2 h. In the absence of the T174M variant (BB genotype), the 405-bp PCR product remained intact. The PCR product of individuals homozygous for the T174M variant (bb genotype) was cleaved by Nco I to yield fragments of 146 and 259 bp. Fragments of 146, 259, and 405 bp were apparent for heterozygotes (Bb genotype).
Echocardiographic Examination
Patients with HCM or DCM were subjected to echocardiographic examination. The left ventricular end-diastolic dimension (LVEDD) and end-systolic dimension (LVESD), as well as the end-diastolic thicknesses of the interventricular septum (IVS) and the left ventricular posterior wall (LVPW), were determined by M-mode echocardiography. The left ventricular ejection fraction (LVEF) was calculated by the method of Teichholz et al. 32 Left ventricular mass (LVM) was calculated by the method of Devereux and Reichek, 33 and the LVM index (LVMI) was calculated by dividing LVM by body surface area. Subjects for whom a high quality echocardiogram could not be obtained were excluded from the echocardiographic study.
Statistical Analysis Data are presented as means Ϯ SD. Age and BMI were compared among healthy control subjects and patients with HCM or DCM by oneway analysis of variance and Scheffé's multiple range test. Allele frequencies were estimated by the gene counting method and analyzed by the 2 test. HardyWeinberg equilibrium was also confirmed by 2 test. Echocardiographic data were compared among ACE or angiotensinogen genotypes or haplotypes by oneway analysis of variance and Scheffé's multiple range test. A level of P Ͻ .05 was considered statistically significant.
RESULTS
Frequencies of ACE I/D Genotypes
The distribution of ACE genotypes in the study population is shown in Table 1 . For the 122 healthy individuals, the frequencies of the II, ID, and DD genotypes were 41%, 45%, and 14%, respectively, and were in Hardy-Weinberg equilibrium. The frequencies of ACE genotypes did not differ significantly among healthy controls and subjects with HCM or DCM. Analyses assuming additive, dominant, or recessive effects of the D allele failed to show any association with HCM or DCM (data not shown).
Frequencies of Angiotensinogen M235T and T174M
Genotypes The distributions of angiotensinogen M235T and T174M genotypes are also shown in Table 1 . In healthy controls, the frequencies of the AA, Aa, and aa genotypes for the M235T polymorphism were 2%, 36%, and 62%, respectively, and the frequencies of the BB, Bb, and bb genotypes for the T174M polymorphism were 80%, 20%, and 0%, respectively. The distributions of both genotypes in normal subjects were in Hardy-Weinberg equilibrium. The distributions of either genotype did not differ significantly among control subjects and patients with HCM or DCM. Analyses assuming additive, dominant, or recessive effects of the a or b allele failed to show any association with HCM or DCM (data not shown).
Analysis of Combined Genotypes and Haplotypes
To examine whether polymorphisms of ACE and angiotensinogen genes exhibit additive or synergistic effects, we determined the distributions of combined genotypes and haplotypes ( Table 2 ). The distributions of either combined genotypes or haplotypes did not differ significantly among control individuals and patients with HCM or DCM.
ACE and Angiotensinogen Genotypes and Echocardiographic Characteristics
The relationship between ACE and angiotensinogen genotypes and left ventricular function determined by echocardiography was investigated in patients with HCM or DCM (Tables 3 to 5 ). Echocardiographic measurements did not differ significantly among ACE genotypes (Table 3 ) or angiotensinogen M235T (Table 4) or T174M (Table 5 ) genotypes in individuals with HCM or DCM.
ACE and Angiotensinogen Haplotypes and Echocardiographic Characteristics
Finally, we determined the relation between haplotypes of ACE and angiotensinogen genes and echocardiographic characteristics (Table 6 ). The only significant association detected was that IVS thickness was greater in HCM patients with the I/A/B haplotype than in those without D/a/b or I/A/B haplotypes.
DISCUSSION
Nonfamilial HCM and DCM may have multifactorial etiologies resulting from an interaction between genetic and environmental influences. In an attempt to identify genes that underlie these cardiomyopathies, we have now shown that the ACE I/D and the angiotensinogen M235T and T174M polymorphisms, either singly or in combination, do not appear to contribute to genetic susceptibility to HCM or DCM in Japanese subjects.
Marian et al 23 demonstrated an association of the DD genotype of ACE with HCM in whites. These researchers suggested that the higher frequency of the D allele in patients with mutations in the ␤-myosin heavy chain gene and a pronounced family history of sudden cardiac death indicates that gene-to-gene interactions may account for the variable clinical mani- 24 showed that the ACE gene modifies the phenotypic expression of hypertrophy in HCM patients and accounts for a fraction of the interfamilial and intrafamilial variability in the extent of hypertrophy in these individuals. Pfeufer et al 34 also observed an association of the ACE DD genotype with HCM, and further showed that the presence of the heart chymase/B GG genotype reduced, whereas that of the AA or AG genotype increased, the relative risk associated with the ACE DD genotype. These data suggest that the heart chymase locus also modifies disease susceptibility in patients with HCM. Yoneda et al 25 showed that the frequency of the ACE D allele was higher in patients with sporadic HCM than in individuals with familial HCM or control subjects in the Japanese population. However, we did not detect a significant difference in the distribution of ACE genotypes between control subjects and patients with HCM. In addition, echocardiographic parameters, indicators of the extent of hypertrophy and impaired left ventricular contractility, did not differ significantly among ACE genotypes for HCM patients. Although the reasons for the discrepancies among the present and previous studies [23] [24] [25] 34 are unclear, our results indicate that the ACE I/D polymorphism is not related to the prevalence or severity of HCM and is not a major contributor to the etiology of HCM in the Japanese population.
Raynolds et al 26 showed that the ACE DD genotype is a risk factor for the development of end-stage heart failure caused by ischemic or idiopathic DCM. However, Montgomery et al 27 failed to detect an association between ACE genotype and either the diagnosis of idiopathic DCM or the progression of the disease in Caucasians. Sanderson et al 28 also did not detect an increase in the frequency of the ACE DD genotype in Chinese subjects with either idiopathic or ischemic DCM. We did not observe a significant difference in the distribution of ACE genotypes between control subjects and patients with DCM. In addition, echocardiographic parameters did not differ significantly among ACE genotypes for DCM patients. These results indicate that the ACE I/D polymorphism is not related to the prevalence or progression of DCM in Japanese subjects, consistent with the results of the latter two studies. 27, 28 Jeunemaitre et al 29 demonstrated an association of the angiotensinogen M235T and T174M variants with essential hypertension. Caulfield et al 35 detected linkage and an association between the angiotensinogen gene locus and essential hypertension, but they failed to demonstrate an association of the M235T or T174M variants with the disease. The M235T variant of the angiotensinogen gene has also been associated with preeclampsia 36 and coronary artery disease. 37 In the present study, the distribution of neither the M235T nor the T174M genotypes differed significantly among control subjects and patients with HCM or DCM. For HCM and DCM subjects, echocardiographic measurements also did not differ among genotypes of M235T or T174M. These results indicate that neither the M235T nor the T174M polymorphism of the angiotensinogen gene is related to the prevalence or progression of nonfamilial HCM or DCM.
Kamitani et al 38 showed that combined analysis of the ACE DD and angiotensinogen aa genotypes enhanced the predictability of myocardial infarction. We also attempted to analyze the association of the combined genotypes of ACE and angiotensinogen polymorphisms. However, we did not detect an additive or synergistic effect of any combined genotype or haplotype on the association with HCM or DCM.
In conclusion, we failed to detect an association of the ACE I/D or angiotensinogen M235T and T174M polymorphisms with HCM or DCM in the Japanese population. Our results indicate that these polymorphisms likely do not contribute to the genesis and progression of these cardiomyopathies.
